{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Herpes-2 IgG"
    ],
    "Submitter Information": "Biokit, S.A.",
    "510(k) Number": "K183334",
    "Predicate Device Reference 510(k) Number(s)": [
        "K000238"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MYF"
    ],
    "Summary Letter Date": "May 17, 2018",
    "Summary Letter Received Date": "May 25, 2018",
    "Submission Date": "May 17, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.3305"
    ],
    "Regulation Name(s)": [
        "Herpes simplex virus serological assays"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to herpes simplex virus type 2 (HSV-2)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur systems",
        "ADVIA Centaur XP"
    ],
    "Method(s)/Technology(ies)": [
        "Two-step sandwich immunoassay",
        "Indirect chemiluminometric technology"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Herpes-2 IgG assay for qualitative determination of IgG antibodies to HSV-2 using chemiluminescent immunoassay on ADVIA Centaur systems.",
    "Indications for Use Summary": "For in vitro qualitative detection of IgG antibodies to HSV-2 in human serum and plasma (EDTA and lithium heparin), aiding in the presumptive diagnosis of HSV infection in sexually active adults or expectant mothers.",
    "fda_folder": "Microbiology"
}